# SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure

> **NCT07311408** · PHASE2 · RECRUITING · sponsor: **Jingdong Zhang** · enrollment: 40 (estimated)

## Conditions studied

- Gastric Cancer (GC)
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** SHR-1701+Rivoceranib + SHR-2554
- **DRUG:** SHR-1701 + Rivoceranib

## Key facts

- **NCT ID:** NCT07311408
- **Lead sponsor:** Jingdong Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311408, "SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07311408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*